A Prospective, Multicenter, Single-arm Clinical Study of NovoClasp Transcatheter Mitral Valve Clip and Steerable Guide Catheter for Treating Moderate to Severe and Severe Degenerative Mitral Regurgitation (DMR)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 102
- 试验地点
- 1
- 主要终点
- Treatment effectiveness rate
研究概览
简要总结
To validate the safety and efficacy of transcatheter edge-to-edge repair (TEER) using the NovoClasp® transcatheter mitral valve clip and steerable guide catheter in the treatment of moderate to severe and severe degenerative mitral regurgitation (DMR).
详细描述
This trial is a prospective multi-center single-arm confirmatory study. A total of 102 subjects will be enrolled in multiple centers nationwide. Subjects who meet the trial requirements, fulfill the inclusion criteria, voluntarily participate in the study, and provide informed consent will undergo mitral edge-to-edge repair using the NovoClasp® transcatheter mitral valve clip system and steerable guide catheter for the treatment of moderate to severe or severe degenerative mitral regurgitation (DMR). Follow-up assessments will be conducted at discharge, as well as at 30 days, 90 days, 180 days, and 360 days postoperatively. The primary endpoint will be the treatment effectiveness rate at 360 days post-surgery. Secondary endpoint measures include treatment effectiveness at other time points, surgical success rate, all-cause mortality, device/procedure-related mortality, incidence of adverse events, and serious adverse event rates. The trial aims to comprehensively assess the safety and efficacy of the NovoClasp® transcatheter mitral valve clip and steerable guide catheter produced by Enlight Medical Technologies (Shanghai) Co., Ltd..
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must meet all of the following criteria to be eligible for this study.
- •Age 18 years.
- •Willingness to comply with the protocol requirements and data collection procedures, ability to understand the purpose of the trial, voluntary participation, and signing of informed consent by the subject or legal guardian.
- •Confirmation by echocardiography of moderate to severe (3+) or severe (4+) degenerative mitral regurgitation.
- •Echocardiography showing left ventricular ejection fraction 30%, left ventricular end-systolic diameter (LVESD) 60mm, and pulmonary artery systolic pressure (PASP) 70 mmHg.
- •NYHA functional classification II-IV.
- •Presence of a primary regurgitant jet; if a secondary regurgitant jet is present, it should be clinically insignificant based on investigator assessment.
- •Evaluated by a multidisciplinary team as suitable for the investigational procedure using the study device.
- •Society of Thoracic Surgeons (STS) score 4 or evaluated as high surgical risk for mitral valve repair by two cardiac surgeons.
排除标准
- •Subjects meeting any of the following criteria are not eligible for this study.
- •History of prior mitral valve surgery or heart transplant.
- •Severe organ dysfunction that may affect study evaluation, including but not limited to:
- •Right heart failure or biventricular heart failure.
- •Severe restrictive or obstructive lung disease (COPD) requiring continuous oxygen therapy or oral steroid treatment.
- •Severe renal insufficiency requiring or likely to require continuous renal replacement therapy (CRRT) or dialysis postoperatively.
- •Severe carotid artery stenosis confirmed by imaging to be >70%.
- •History of cerebrovascular accident within the past 1 month.
- •Acute deep vein thrombosis or acute pulmonary embolism history.
- •Any known active infection.
- •Active infective endocarditis (eligible 6 weeks after standard antimicrobial treatment), rheumatic heart valve disease, or radiation-induced valve disease.
- •Cardiac or major vascular surgical or interventional procedure within 30 days (coronary angiography is allowed).
- •Coexisting moderate or greater valvular disease (aortic valve, tricuspid valve, pulmonary valve stenosis or regurgitation).
- •Known other cardiac or major vascular diseases requiring surgical or interventional intervention, including but not limited to coronary artery disease, myocardial disease, aortic disease (except for coronary angiography).
- •Echocardiographic evidence of intracardiac mass, thrombus, vegetation, or mitral valve orifice area (MVOA) 4.0 cm2, or any condition unsuitable for the study device, including but not limited to:
- •Unsuitable for leaflet capture due to severe calcification or cleft.
- •Lack of primary and secondary chordal support in the capture area.
- •Leaflet free edge length < 0.8 cm.
- •Known conditions that preclude study procedure (including but not limited to allergies to device components, coagulation disorders, life expectancy < 1 year).
- •Pregnant or breastfeeding women or those planning pregnancy during the trial period.
- •Intending or currently participating in another interventional clinical trial.
- •Other conditions deemed inappropriate for participation in this study by the investigator.
结局指标
主要结局
Treatment effectiveness rate
时间窗: 1 year
Treatment effectiveness is defined as the success of the procedure with the mitral valve regurgitation sustained at moderate or lower (\<=2+) after the surgery, without major adverse events or secondary interventions (interventional or surgical).
次要结局
- Rate of Treatment success(30 days, 180 days)
- Procedural success rate(During the perioperative period)
- Changes in New York Heart Association (NYHA) Functional Classification(through study completiong, an average of 1 year.)